Kronos is cutting 83% of its workforce, while Idorsia is considering eliminating as many as 270 jobs. Elsewhere, PTC ...

The biotechnology company, which sees itself as "pretty conservative," recently put out an ambitious long-term revenue ...

A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...

Dublin/Frankfurt, 27 November, 2024 - Merz Therapeutics launches iFlexo, a personalized digital solution aimed at enhancing ...

The deal suggests Roche sees substantial promise in Poseida’s technology, as the offer is 215% above the biotech’s closing ...

Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...

Long-awaited results released Tuesday showed adding tiragolumab to Roche's immunotherapy Tecentriq did not extend survival in ...

A prolific medical research and author, Martin Makary criticized the FDA and CDC for their decision-making during the ...

BridgeBio shares climbed by nearly 25% Monday on news its drug for a cardiac form of transthyretin amyloidosis was approved ...

Positive study results for Winrevair could help the drugmaker achieve sales growth past top-seller Keytruda’s upcoming patent ...

The setback likely removes one competitor to an emerging spinal muscular atrophy medicine from Scholar Rock, but sets the ...

In buying Westlake-backed Kate Therapeutics, Novartis gets a handful of preclinical gene therapies targeting diseases like ...